SCHEMBL19110331

SCHEMBL19110331

c1ccc2c(c1)sc1cc(-c3c4ccccc4c(-c4ccc5sc6cc7ccc8sc9ccccc9c8c7cc6c5c4)c4ccccc34)ccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GPR3 P46089 1/20 0.38
POLB P06746 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
DUSP3 P51452 2/20 0.35
MEN1 O00255 1/20 0.35
BLM P54132 1/20 0.35
PTPN5 P54829 1/20 0.35
KMT2A Q03164 1/20 0.35
PTPN11 Q06124 1/20 0.35
MCL1 Q07820 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
NQO1 P15559 1/20 0.33
NQO2 P16083 1/20 0.33
PTPN1 P18031 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19110322 0.99 MAPT (0.41) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL24341039 0.95 MAPT (0.38) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL19109145 0.94 MAPT (0.37) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL19109118 0.94 MAPT (0.37) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL19110323 0.93 MAPT (0.41) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL24342715 0.92 MAPT (0.35) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL24343191 0.92 GPR3 (0.40) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL24341897 0.92 ESR1 (0.34) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL24341467 0.91 ESR1 (0.36) MAPTALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL22680415 0.91 ESR1 (0.37) MAPTALDH1A1HPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11276827-B2 Condensed cyclic compound and an organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2022-03-15 US disclosed
US-20170200905-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2017-07-13 US disclosed
US-20170200905-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2017-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170200905-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CRY2, CCNA1 MAPT 1538/4885ALDH1A1 237/4885HPGD 1696/4885
US-11276827-B2 Condensed cyclic compound and an organic light-emitting device including the same CRY1, CRY2, CCNA1 MAPT 1538/4885ALDH1A1 237/4885HPGD 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.